CN112236454B - 新型抗pd-1抗体 - Google Patents

新型抗pd-1抗体 Download PDF

Info

Publication number
CN112236454B
CN112236454B CN201980020380.6A CN201980020380A CN112236454B CN 112236454 B CN112236454 B CN 112236454B CN 201980020380 A CN201980020380 A CN 201980020380A CN 112236454 B CN112236454 B CN 112236454B
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
vhh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980020380.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112236454A (zh
Inventor
陈蕴颖
李竞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Shanghai Co Ltd
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Priority to CN202211052114.1A priority Critical patent/CN116333126A/zh
Publication of CN112236454A publication Critical patent/CN112236454A/zh
Application granted granted Critical
Publication of CN112236454B publication Critical patent/CN112236454B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980020380.6A 2018-03-20 2019-03-18 新型抗pd-1抗体 Active CN112236454B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211052114.1A CN116333126A (zh) 2018-03-20 2019-03-18 新型抗pd-1抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/079631 2018-03-20
CN2018079631 2018-03-20
CN201810255570 2018-03-20
CN2018102555703 2018-03-20
PCT/CN2019/078515 WO2019179396A1 (en) 2018-03-20 2019-03-18 Novel anti-pd-1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211052114.1A Division CN116333126A (zh) 2018-03-20 2019-03-18 新型抗pd-1抗体

Publications (2)

Publication Number Publication Date
CN112236454A CN112236454A (zh) 2021-01-15
CN112236454B true CN112236454B (zh) 2022-09-13

Family

ID=67986701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211052114.1A Pending CN116333126A (zh) 2018-03-20 2019-03-18 新型抗pd-1抗体
CN201980020380.6A Active CN112236454B (zh) 2018-03-20 2019-03-18 新型抗pd-1抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211052114.1A Pending CN116333126A (zh) 2018-03-20 2019-03-18 新型抗pd-1抗体

Country Status (7)

Country Link
US (2) US12030941B2 (enExample)
EP (1) EP3768724A4 (enExample)
JP (2) JP7482031B2 (enExample)
CN (2) CN116333126A (enExample)
CA (1) CA3093992A1 (enExample)
TW (1) TWI829677B (enExample)
WO (1) WO2019179396A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7482031B2 (ja) * 2018-03-20 2024-05-13 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－１抗体
CN112442122B (zh) * 2019-09-04 2021-09-21 上海洛启生物医药技术有限公司 阻断型pd-1纳米抗体及其编码序列和用途
EP4034568A4 (en) * 2019-09-25 2024-02-14 Wuxi Biologics Ireland Limited Novel anti-pd-l1 antibodies
JP2022550243A (ja) * 2019-09-30 2022-12-01 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｐｄ－１抗体及びその使用
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
CN118240082A (zh) * 2020-12-28 2024-06-25 浙江纳米抗体技术中心有限公司 Pd-1结合分子及其应用
WO2022141378A1 (zh) * 2020-12-31 2022-07-07 浙江道尔生物科技有限公司 一种抗pd-1的单域抗体
US20240309093A1 (en) * 2021-01-29 2024-09-19 Minghui Pharmaceutical (Hangzhou) Limited Antigen binding protein and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2009114335A2 (en) * 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CN106432494B9 (zh) 2015-08-11 2022-02-15 广州誉衡生物科技有限公司 新型抗-pd-1抗体
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
CN106046162B (zh) * 2016-06-21 2019-04-02 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
CN107474135B (zh) * 2017-02-17 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb20及其制备方法与应用
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
JP7482031B2 (ja) * 2018-03-20 2024-05-13 ウーシー バイオロジクス アイルランド リミテッド 新規の抗ｐｄ－１抗体

Also Published As

Publication number Publication date
US20240301067A1 (en) 2024-09-12
CN116333126A (zh) 2023-06-27
EP3768724A4 (en) 2022-04-13
US12030941B2 (en) 2024-07-09
CN112236454A (zh) 2021-01-15
TWI829677B (zh) 2024-01-21
JP7482031B2 (ja) 2024-05-13
US20210061912A1 (en) 2021-03-04
WO2019179396A1 (en) 2019-09-26
JP2024029261A (ja) 2024-03-05
CA3093992A1 (en) 2019-09-26
TW202003563A (zh) 2020-01-16
JP2021518137A (ja) 2021-08-02
EP3768724A1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
CN112236454B (zh) 新型抗pd-1抗体
CN110204614B (zh) 抗人lag-3单克隆抗体及其制备方法和用途
TWI831778B (zh) 抗ox40的全人抗體及其製備方法和用途
CN114206935A (zh) 新型cldn18.2结合分子
CN114430746B (zh) 新型抗pd-l1抗体
CN112480248A (zh) 与cld18a2特异性结合的分子
CN111978402B (zh) 新型cldn18.2结合分子
CN113214400B (zh) 一种双特异性抗pd-l1/vegf抗体及其用途
CN111978403A (zh) 新型cldn18.2结合分子
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
CN119256010A (zh) 抗b7h3抗体及其用途
CN115175942A (zh) 一种双功能融合蛋白及其用途
HK40044140B (en) Novel anti-pd-1 antibodies
HK40044140A (en) Novel anti-pd-1 antibodies
HK40033235A (en) Novel cldn18.2 binding molecule
HK40076079A (en) Antibodies against human lag-3 and uses thereof
HK40032484A (en) Novel cldn18.2 binding molecule
HK40032484B (en) Novel cldn18.2 binding molecule
CN118047869A (zh) 抗pd-l1抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044140

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant